“Targeting”renal cell carcinoma patients with“targeted”agents:Are we there yet?

• 作者: Alessandra Felici Emilio Bria Francesca Maines Francesco Massari Giampaolo Tortora Michele Milella Sara Pilotto Vanja Vaccaro
• 来源期刊: 世界临床泌尿杂志
• 学科: 医学
• 关键词: Biomarkers Renal cell carcinoma Prognostic BIOMARKER Predictive BIOMARKER Vascular endothelial growth factor TYROSINE kinase INHIBITORS MAMMALIAN target of RAPAMYCIN INHIBITORS
• 年，卷（期）: 2014,（1）
• 页码范围: 9-19
• 页数: 11页
• 分类号: R

摘要

The rapid approval of several novel agents,targeting the vascular endothelial growth factor or mammalian target of rapamycin pathways(sunitinib,pazopanib,sorafenib,axitinib,bevacizumab,everolimus,temsirolimus)has given to metastatic renal cell carcinoma(mRCC)patients and their treating physicians many new and effective therapeutic options.The treatment paradigm for these patients is rapidly evolving,with future studies needed to define the optimal sequencing of these new agents.Despite progresses,no validated biomarkers able to predict clinical outcome or useful to guide patient selection for treatment are currently available.Recent studies have suggested that some biomarkers,including cytokines,circulating proangiogenic factors,markers of hypoxia or targets of signaling pathways are potentially promising prognostic or predictive factors in mRCC.We present an overview of the most recent developments in identifying biomarkers for targeted therapies in advanced RCC.